Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Silo Pharma Inc (OP: SILO )

N/A UNCHANGED
Last Price Updated: 3:23 PM EDT, Sep 14, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Silo Pharma Inc

< Previous 1 2 3 4 Next >
Silo Pharma Inc. (SILO) Produced Initial Liposome Batch for Rheumatoid Arthritis Study
Via Investor Brand Network
BioMedNewsBreaks – Silo Pharma Inc. (SILO), UMB Collaborating on Potentially Significant Homing-Peptide Technology
Via Investor Brand Network
Study Says Ayahuasca Users Tend to Exercise More, Eat Healthier
Via Investor Brand Network
Topics Religion
Exposures Religion
Study Finds That Microdosing Psilocybin Mushrooms Improves Mood, Mental Health
Via Investor Brand Network
Homing Peptides: Silo Pharma Inc. (SILO) Targets ADRs
Via Investor Brand Network
Silo Pharma Inc. (SILO) Takes Aim at Alzheimer’s Disease
Via Investor Brand Network
Study Suggests COVID-19 Increases Parkinson’s Disease Risk
Via Investor Brand Network
Exposures COVID-19
New Research Suggests Mental Disorders Magnify Dementia Risk
Via Investor Brand Network
Study Maps How Brain Changes During Treatment for Depression
Via Investor Brand Network
BioMedNewsBreaks – Silo Pharma Inc. (SILO) Announces Positive Results of New Study
Via Investor Brand Network
DEA Sets Hearing Date Regarding Plan to Ban Several Psychedelics
Via Investor Brand Network
BioMedNewsBreaks – Silo Pharma Inc. (SILO) Bringing Hope, Possible Therapeutic to Alzheimer’s Patients
Via Investor Brand Network
Federal Health Agencies Admit That Classification of Psychedelics Is Impeding Research
Via Investor Brand Network
Brain Cell Regulation Mechanism Could Unlock Novel Treatment Modalities for Neurological Conditions
Via Investor Brand Network
New Report Says Smoking Amplifies Schizophrenia and Depression Risk
Via Investor Brand Network
What Investors Interested in Psychedelics Need to Focus on Regarding IP Issues
Via Investor Brand Network
Topics Cannabis Intellectual Property
Exposures Cannabis Intellectual Property
PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Announces Expansion of License Agreement and Patent Portfolio
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Study Finds Frequent Nightmares May Be Sign of Parkinson’s Disease Development
Via Investor Brand Network
New Study Finds Dose Tapering May Heighten Risk of Opioid Overdoses
Via Investor Brand Network
Mystical Experiences Due to Psilocybin Linked to Positive Mental Well-Being
Via Investor Brand Network
Study Says Damage to Neurons, Not Plaque Triggers Alzheimer’s Onset
Via Investor Brand Network
Topics Death
Exposures Death
Five Books on Psychedelics You May Enjoy Reading
Via Investor Brand Network
PsychedelicNewsBreaks – Silo Pharma Inc. (SILO) Committed to Psilocybin, Anti-Inflammatory Research
Via Investor Brand Network
Study Offers New Insights into Psilocybin’s Mechanism for Treating Depression
Via Investor Brand Network
At least 4 in 10 Long-COVID Patients Report Symptoms Akin to Fibromyalgia
Via Investor Brand Network
Exposures COVID-19
UK Firm Develops Inhaler to Facilitate Psychedelic Microdosing
Via Investor Brand Network
UC Davis Awarded Grant to Find New Non-hallucinogenic Psychedelic Treatments for Addiction
Via Investor Brand Network
Silo Pharma Inc. (SILO) Focuses on Psilocybin’s Anti-Inflammatory Properties
Via Investor Brand Network
Davos Hosts Psychedelic Medical Series
Via Investor Brand Network
Exposures COVID-19
BioMedNewsBreaks – Silo Pharma Inc. (SILO) Bringing Hope to Patients Suffering from Alzheimer’s and Potentially Other Ailments
Via Investor Brand Network
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.